MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Earnings for MaxCyte, Inc. (MXCT)
Earnings in 2023 (TTM): $-37,923,000
According to MaxCyte, Inc.'s latest financial reports the company's current earnings (TTM) are $-37,923,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of MaxCyte, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-37,923,000 | $-37,923,000 |
| 2022 | $-23,570,800 | $-19,781,100 |
| 2021 | $-19,082,200 | $-20,126,600 |
| 2020 | $-11,816,400 | $-12,642,000 |
| 2019 | $-12,895,000 | $-13,576,100 |
| 2018 | $-8,869,200 | $-8,869,200 |
| 2017 | $-9,917,000 | $-9,917,000 |
| 2016 | $-3,345,500 | $-3,345,500 |
| 2015 | $-1,445,500 | $-1,445,500 |
| 2014 | $-1,837,000 | $-1,837,000 |
| 2013 | $-958,200 | $-958,200 |
| 2012 | $-1,988,400 | $-1,988,400 |